Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.
Vol 86 • 2025 • Number 3
Read the Current Issue
Original Research
Treatment Use and Preference in a Diverse Sample of Women With Mood Disorders
Original Research
Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders
Original Research
Niacin-Induced Response in Early Psychosis
Original Research
Early Ketamine Response Reduces Suicidal Events at 3 Months
Letter to the Editor
Suicide Risk among Patients with Bipolar Disorder: Sleep Disruption versus Benzodiazepine Use
Original Research
Effect of Nature Videos on the Burden of Caregivers of Patients with Dementia
Related Articles
Insights
Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video
January 14, 2023
Evaluating different domains of negative symptoms separately to better understand their impact on functional outcomes, particularly cognitive symptoms, is important in the treatment of patients with schizophrenia, especially intervening...
Insights
Sequencing Therapy in the Treatment of Schizophrenia Video
January 14, 2023
Balancing and optimizing safety and efficacy when treating patients with schizophrenia can be challenging. New approaches to treatment may impact symptoms more effectively and contribute to better adherence. Sequencing,...
